Navigating Leukemia Treatment: Is Blinatumomab a Cost-Effective Choice?
"A closer look at the cost-effectiveness of blinatumomab versus inotuzumab for adults battling relapsed or refractory acute lymphoblastic leukemia."
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects the blood and bone marrow. When ALL returns after treatment (relapsed) or doesn't respond to initial treatment (refractory), finding the right therapy becomes critical. Blinatumomab and inotuzumab ozogamicin are two such treatments used in adults with relapsed or refractory (R/R) ALL.
The challenge for healthcare providers and patients is determining which treatment offers the best value, considering both its effectiveness and cost. This is where cost-effectiveness analysis comes in, helping to weigh the benefits against the financial burden.
This article delves into a study comparing the cost-effectiveness of blinatumomab versus inotuzumab in adult patients with R/R ALL who have undergone zero or one prior salvage therapy. By examining the incremental cost-effectiveness ratio (ICER), we aim to shed light on whether blinatumomab represents a worthwhile investment from a US payer perspective.
Economic Burden and Treatment Costs
Economic evaluations of leukemia-related treatment commonly model progression-free survival, overall survival, time to next treatment, costs, and utilities across health states. One 2022 analysis discounted these inputs at 3.0% per year when assessing treatment effectiveness and economic outcomes. Research on chronic lymphocytic leukemia reports that oral targeted therapies represent a significant treatment advance, but their high cost raises concerns about affordability and broader societal impact. US studies using Optum’s de-identified Clinformatics Data Mart Database have examined treatment patterns, healthcare resource utilization, and healthcare costs associated with CLL/SLL.
How Cost-Effectiveness Is Assessed
Cost-effectiveness assessments generally compare treatment costs with clinical outcomes and quality-of-life effects. They may account for survival, disease progression, healthcare use, and costs borne by health systems or patients. However, results can depend on modeling assumptions, the time horizon selected, and the quality of available clinical and economic data. These limitations mean that economic findings should be interpreted as estimates rather than universal conclusions.
From Blood-Cell Discovery to Targeted Therapy
Accounts of leukemia’s history trace the field from early descriptions of unusual blood cells and clinical disorders in the 19th century to contemporary genetic and epigenetic insights. The history of childhood leukemia is especially associated with major milestones in diagnosis and treatment. More recent developments include targeted therapies such as imatinib, reflecting the shift from broad disease descriptions toward biologically informed treatment. Recent reviews also emphasize that understanding of leukemia continues to evolve alongside research into viruses, bacteria, and genetic mutations.
Blinatumomab vs. Inotuzumab: A Cost-Effectiveness Comparison
The study utilized a matching-adjusted indirect treatment comparison (MAIC) of the TOWER and INO-VATE-ALL trials to estimate the ICER (cost per QALY gained) of blinatumomab compared to inotuzumab. A partitioned-survival model was employed, incorporating data from both trials, adjusted via MAIC to ensure comparable patient characteristics.
- Analysis 1: Compared inotuzumab overall survival (OS) using a MAIC-adjusted hazard ratio to blinatumomab MAIC-adjusted TOWER OS.
- Analysis 2: Assessed inotuzumab and standard-of-care (SOC) OS against blinatumomab OS, applying a MAIC-adjusted hazard ratio.
- Analysis 3: Performed an unanchored comparison of MAIC-adjusted blinatumomab OS from TOWER and inotuzumab OS from INO-VATE-ALL.
Recent Cost-Effectiveness Evidence
A 2025 scoping review surveys cost-effectiveness evidence for precision treatment in chronic lymphocytic leukemia. It examined economic evaluations indexed in PubMed, Embase, and Web of Science and published through October 2024. The review identifies both the existing evidence base and areas requiring further research. A 2023 study separately evaluated first-line venetoclax plus obinutuzumab, chlorambucil plus obinutuzumab, and ibrutinib for CLL with significant comorbidity and without TP53 aberrations, including the costs and effects of second-line treatment.
Limits of Economic Evidence
Reviews of cost-effectiveness analyses in acute myeloid leukemia use azacitidine plus venetoclax and liposomal cytarabine plus daunorubicin to discuss how such studies should be conducted and interpreted. A holistic assessment should consider whether treatment costs translate into increased survival, reduced symptom burden, fewer emergency or inpatient treatments, and less caregiver strain. Other reviews emphasize that new therapies improving survival and health-related quality of life can also alter the economic burden of difficult-to-treat AML populations. These considerations show why favorable clinical results do not automatically establish cost-effectiveness from every perspective.
Comparing Treatment Value
Comparative analysis should weigh treatment costs against differences in survival, quality of life, symptom control, and healthcare utilization. It should also distinguish the perspective used, such as that of a health system, payer, patient, or society. Because these analyses depend on clinical evidence and economic assumptions, one treatment may appear favorable under one perspective or time horizon and less favorable under another. Direct conclusions about blinatumomab therefore require comparable evidence for the alternatives being evaluated.
The Verdict: Is Blinatumomab a Cost-Effective Option?
The results of all three analyses indicated that blinatumomab was more effective (incremental QALYs ranging from 0.59 to 1.89) and slightly more costly (incremental costs between $27,021 and $29,021). This resulted in ICERs of $14,341, $49,131, and $24,952 per QALY gained, respectively.
Balancing Value and Affordability
The value of a hematologic cancer therapy involves more than its acquisition price. New drugs can offer varying levels of expected therapeutic efficacy while increasing costs for patients and payers. As novel therapies become more common and prices rise, the concept of value has moved to the center of treatment decision-making. Evaluating blinatumomab therefore requires considering its expected therapeutic benefits alongside its financial effects.
Emerging Leukemia Research
The National Cancer Institute identifies targeted therapies and immunotherapies as active areas of leukemia research. Its research overview also highlights NCI programs and clinical trials as part of the current development landscape. These advances may expand treatment options and generate new evidence about clinical outcomes. Their eventual economic value will depend on how benefits, risks, and treatment costs compare in practice.
The Cost Burden of Cancer Care
High-cost anticancer therapies can create financial burdens through treatment expenses and other costly medications. The cited review notes that state- and federal-level efforts have sought to address out-of-pocket spending and therapy costs more broadly. This policy context matters when assessing whether a treatment is affordable for patients as well as payers. Cost-effectiveness discussions therefore sit within wider challenges involving access, coverage, and financial protection.
Patients Behind the Economics
Economic evaluations ultimately concern decisions that affect patients, families, and caregivers. Treatment costs may influence access, financial stress, and the practical ability to continue therapy. Clinical benefits such as longer survival or fewer symptoms must therefore be considered alongside affordability and quality of life. Because these effects can vary among individuals, cost-effectiveness findings should support informed discussions rather than replace patient-centered care.
These findings suggest that, across various approaches of applying the MAIC results, blinatumomab can be considered a cost-effective treatment option for adults with R/R ALL who have undergone zero or one prior salvage therapy, from a US payer perspective.
Ultimately, the decision to use blinatumomab should be made in consultation with healthcare professionals, considering individual patient factors and the specific clinical context. However, this analysis provides valuable insights into the economic implications of choosing blinatumomab over inotuzumab for R/R ALL treatment.